ALMS: Alumis Inc.
Performance
ALMS +38.77%
Watchlist
Select an item
Summary
ALMS at a glance
ALMS returned +38.77% over the past year. Its worst drop in that year was -80.69%, smaller than 1% of stocks on Redstone, and its Sharpe ratio of 0.85 beats 68% of stocks on Redstone. It pays no dividends.
Current Drawdown
-78.38%
Rolling Volatility
77.68%
Actions
Metrics
Risk Indicators
Alpha96.93%
Beta1.93x
Sharpe0.85
Sortino1.54
Omega1.24
Calmar0.48
Martin3.21
Profile
About ALMS
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $848M
- Listed
- Jun 2024
- Employees
- 239
- Headquarters
- South San Francisco, CA
- Website
- alumis.com
Comparisons